Literature DB >> 33716105

Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines.

A Vogel1, E Martinelli2.   

Abstract

Entities:  

Year:  2021        PMID： 33716105     DOI： 10.1016/j.annonc.2021.02.014

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  52 in total

1.  First-Line Immune Checkpoint Inhibitor-Based Sequential Therapies for Advanced Hepatocellular Carcinoma: Rationale for Future Trials.

Authors:  Giuseppe Cabibbo; Maria Reig; Ciro Celsa; Ferran Torres; Salvatore Battaglia; Marco Enea; Giacomo Emanuele Maria Rizzo; Salvatore Petta; Vincenza Calvaruso; Vito Di Marco; Antonio Craxì; Amit G Singal; Jordi Bruix; Calogero Cammà
Journal:  Liver Cancer       Date:  2021-11-23       Impact factor: 11.740

2.  Two is better than one: combinatorial receptor targeting enhances hepatocellular carcinoma (HCC) therapeutic response.

Authors:  Celia Sequera; Flavio Maina
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

3.  Identification of HLA-A2 restricted epitopes of glypican-3 and induction of CTL responses in HLA-A2 transgenic mice.

Authors:  Xiaoxiao Jin; Xiaotao Liu; Zining Zhou; Yan Ding; Yandan Wu; Jie Qiu; Chuanlai Shen
Journal:  Cancer Immunol Immunother       Date:  2021-11-01       Impact factor: 6.968

4.  Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.

Authors:  Takeshi Hatanaka; Satoru Kakizaki; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Joji Tani; Masanori Atsukawa; Koichi Takaguchi; Ei Itobayashi; Shinya Fukunishi; Kunihiko Tsuji; Toru Ishikawa; Kazuto Tajiri; Hironori Ochi; Satoshi Yasuda; Hidenori Toyoda; Chikara Ogawa; Takashi Nishimura; Noritomo Shimada; Kazuhito Kawata; Hisashi Kosaka; Takaaki Tanaka; Hideko Ohama; Kazuhiro Nouso; Asahiro Morishita; Akemi Tsutsui; Takuya Nagano; Norio Itokawa; Tomomi Okubo; Taeang Arai; Michitaka Imai; Atsushi Naganuma; Yohei Koizumi; Shinichiro Nakamura; Kouji Joko; Masaki Kaibori; Hiroko Iijima; Yoichi Hiasa; Takashi Kumada
Journal:  Hepatol Int       Date:  2022-06-24       Impact factor: 9.029

5.  TNF-α Indicates Radiation-induced Liver Injury After Interstitial High Dose-rate Brachytherapy.

Authors:  Robert Damm; Maciej Pech; Florian Haag; Paola Cavalli; Severin Gylstorff; Jazan Omari; Ricarda Seidensticker; Jens Ricke; Max Seidensticker; Borna Relja
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

6.  Highlights in Hepatocellular Carcinoma From the 2021 European Society for Medical Oncology Congress: Commentary.

Authors:  Catherine T Frenette
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-11

7.  Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism.

Authors:  Pei-Wei Shueng; Hui-Wen Chan; Wei-Chan Lin; Deng-Yu Kuo; Hui-Yen Chuang
Journal:  Int J Mol Sci       Date:  2022-06-10       Impact factor: 6.208

Review 8.  The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity.

Authors:  Stavros P Papadakos; Nikolaos Dedes; Elias Kouroumalis; Stamatios Theocharis
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

9.  A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2021-10-12       Impact factor: 11.740

10.  Antitumor Effect of Lenvatinib Combined with Alisertib in Hepatocellular Carcinoma by Targeting the DNA Damage Pathway.

Authors:  Jianwen Hao; Qizhen Peng; Keruo Wang; Ge Yu; Yi Pan; Xiaoling Du; Na Hu; Xuening Zhang; Yu Qin; Huikai Li
Journal:  Biomed Res Int       Date:  2021-07-22       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.